Skip to main content
. 2021 May 26;22(11):5673. doi: 10.3390/ijms22115673

Figure 7.

Figure 7

Up-regulation of miR-206 in serum of ALS, SMA, and SBMA patients. (A) Quantitative real-time PCR analysis of myomiRs in total RNA extracted from serum of ALS, pediatric SMA, and SBMA patients (black bars), healthy controls (white bars) and patients with anti-NMDA receptor encephalitis (white bars in the SMA graph) as controls for pediatric SMA. Relative expression data are presented as mean ± SEM of 2−ΔCt values normalized against the endogenous control miR-16. * p < 0.05, ** p < 0.01, Mann–Whitney test. (B) Receiver operating characteristic (ROC) curves used to assess the sensitivity and specificity of miR-206 in serum as biomarker for ALS, SMA, and SBMA.